Array BioPharma to present positive interim results of Phase 1 ARRY-380 trial at ASCO
Array BioPharma Inc. today announced positive interim results of its novel, oral HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in patients with advanced cancer.